Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Immpact Bio Closes $111 Million Series B Financing, Names New Board Chair And New President And Ceo, And Updates On Phase 1 Clinical Study In Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

PRIVATEJan 20, 2022•over 4 years ago

Amount Raised

$111 Million

Round Type

Series B

Camarillo

Description

ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced it has closed $111 million in Series B financing, led by venBio Partners along with co-leads Foresite Capital and Decheng Capital. Surveyor Capital (a Citadel company) also joined this financing round. Additional investors include the company's existing investors OrbiMed, Novartis Venture Fund, RM Global Partners (RMGP), and Bukwang Pharmaceutical

Company Information

Company

Imm Pact Bio

Location

Camarillo, California, United States

About

ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies for cancer patients who have exhausted their treatment options. The company's logic-gate-based CAR T platforms address key biological challenges in treating cancer. ImmPACT Bio's technologies are specifically designed to prevent antigen escape, prevent 'on-target – off-tumor' toxicities, and overcome the immunosuppressive tumor microenvironment. The company's technology is based on the work of pioneering scientists Yvonne Chen, Ph.D., and Antoni Ribas, M.D., Ph.D., both from University of California, Los Angeles (UCLA), and Gideon Gross, Ph.D., from the MIGAL-Galilee Research Institute. For more information, visit www.immpact-bio.com. SOURCE ImmPACT Bio

Don't miss Imm Pact Bio's next move

Get an email the moment Imm Pact Bio raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Imm Pact Bio's next move

Learn about Strategic plan

Funding Insights

Based on industry data
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Imm Pact Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.